


RESEARCH REPORT



MOLECULAR DIAGNOSTICS FOR CANCER.
MARKETS FORECASTS BY CANCER TYPE, PRODUCT AND PLACE
WITH EXECUTIVE AND CONSULTANT GUIDES AND
CUSTOMIZATION.
2023 TO 2027



HOWE SOUND RESEARCH



Howe Sound Research is a market research and consulting company based in Vancouver, British Columbia, Canada. In our spare time we like to sail in a large body of water nearby called Howe Sound. We publish market research reports that address scientific industries with an emphasis on Biotechnology and Clinical Diagnostic markets. We consider ourselves experts in these areas.

We approach market research differently than other companies. At any one time we have a limited number of reports and we update them frequently, sometimes several times a year. Our reports are prepared by people who understand the industry and have worked and studied in the area. This contrasts with the many research mills who produce canned reports on the Handbag market one day and the XRay market the next.

Our intellectual property is encryption protected. If you have issues with this or would like to upgrade to a corporate license that is not encrypted, please contact us at the email above.

Please feel free to contact us if you have any questions. We believe in customer service and are more than willing to provide after sales assistance and custom data.

All Rights Reserved. This document contains copyrighted intellectual property. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of Howe Sound Research.

Please respect our intellectual property and do not distribute this document beyond the terms of your license.

Table of Contents

1	Market Guides	19
1.1	Cancer MDx - Strategic Situation Analysis	20
1.2	Guide for Executives, Marketing, and Business Development Staff	23
1.3	Guide for Management Consultants and Investment Advisors.....	25
2	Introduction and Market Definition	26
2.1	What are Molecular Diagnostics?	27
2.2	The Diagnostics Revolution.....	27
2.3	Market Definition	29
2.3.1	Revenue Market Size.....	29
2.4	Methodology.....	31
2.4.1	Methodology.....	31
2.4.2	Sources.....	31
2.4.3	Authors	31
2.5	Perspective: Healthcare and the IVD Industry	33
2.5.1	Global Healthcare Spending	33
2.5.2	Spending on Diagnostics	34
2.5.3	Important Role of Insurance for Diagnostics.....	35
3	Market Overview.....	36
3.1	Market Segments	37
3.1.1	Traditional Market Segmentation.....	37
3.1.2	Laboratory Focus and Segmentation.....	38
3.2	Industry Structure.....	40
3.2.1	Hospital Testing Share	40
3.2.2	Economies of Scale.....	40
3.2.3	Physician Office Lab's.....	42

3.2.4	Physician's and POCT	42
4	Market Trends	43
4.1	Factors Driving Growth	44
4.1.1	New Diagnostics Create New Markets.....	44
4.1.2	New Roles for Diagnostics.....	45
4.1.3	The Aging Effect	45
4.1.4	Expanding the Pharmaceutical Toolbox.....	47
4.1.5	Regulatory Retreat	47
4.2	Factors Limiting Growth	48
4.2.1	Falling Prices.....	48
4.2.2	Lower Costs.....	49
4.2.3	Wellness has a Downside	49
4.3	Instrumentation, Automation and Diagnostic Trends	50
4.3.1	Traditional Automation and Centralization.....	50
4.3.2	The New Automation, Decentralization and Point Of Care	50
4.3.3	Instruments Key to Market Share	52
4.3.4	Bioinformatics Plays a Role	52
4.3.5	PCR Takes Command	52
4.3.6	Next Generation Sequencing Fuels a Revolution.....	53
4.3.7	NGS Impact on Pricing.....	54
4.3.8	Whole Genome Sequencing, A Brave New World	54
4.3.9	Companion Diagnostics Blurs Diagnosis and Treatment	54
4.3.10	Shifting Role of Diagnostics.....	55
4.3.11	Multiplexing and Foundation One	57
4.3.12	Pharmacogenomics Technology	57
4.3.13	Gene Editing and Gene Therapy.....	58
5	Molecular Diagnostics Recent Developments	59
5.1	Recent Developments – Importance and How to Use This Section	60

5.1.1	Importance of These Developments	60
5.1.2	How to Use This Section.....	60
5.2	Grail Cancer Test Faces New Clinical Questions.....	60
5.3	Freenome Acquires Cancer Dx Firm Oncimmune	63
5.4	Quest Diagnostics to Acquire Liquid Biopsy Firm Haystack Oncology	64
5.5	Ultima Genomics, Genome Insight Partner on WGS for Cancer Patients.....	64
5.6	Digital Pathology Meets Cancer Sequencing.....	65
5.7	Exact Sciences Preps Expanded Oncology Portfolio.....	70
5.8	Qiagen Details Oncology Plans for Digital PCR Platform	72
5.9	Sema4 Exiting Reproductive Health Screening	75
5.10	Thermo Fisher Introduces Cancer Profiling Assay	77
5.11	Genomic Test IDs Cysts Likely to Progress to Cancer	78
5.12	Naveris to Commercialize Virus-Related Cancer Tests	81
5.13	Larger Liquid Biopsy Panels Loom	81
5.14	Halo Diagnostics to Offer Genomic Profiling Tests.....	87
5.15	BillionToOne Raises \$125M	88
5.16	Local Cancer Genomic Profiling Options Grow	88
5.17	German MDx Firm Mainz Biomed Raises \$10M in IPO	94
5.18	Guardant Health Q3 Revenues Up 27 Percent	95
5.19	BforCure Raises \$2.3M to Adapt Rapid PCR Platform for Cancer Detection.....	96
5.20	Nucleix to Invest in Early-Stage Lung Cancer Dx.....	97
5.21	Labcorp, GeneCentric Partnering on Development of RNA-Based Cancer Diagnostics.....	99
5.22	Grail Gets Approval for Galleri Multicancer Test	100
5.23	Finnish Firms to Form Point-of-Care Testing Firm	100
5.24	Datar Cancer Genetics Expands to Dx and Screening.....	101
5.25	HTG Molecular Diagnostics: HTG Transcriptome Panel.....	105
5.26	PacBio's Omniome Acquisition Shortens Path to Clinical	106

5.27	Invitae to Acquire Genosity for \$200M	108
5.28	Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test	109
5.29	Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience.....	110
5.30	Natera Revenues Grow 35 Percent	111
5.31	AnchorDx Closes \$40M Financing Round	111
5.32	Exact Sciences Strategy for End-to-End Cancer Testing	112
5.33	Genomics England: Whole Genome Sequencing for Cancer Patients to Launch..	115
6	Profiles of Key MDx Companies	119
6.1	10x Genomics, Inc.....	120
6.2	Abbott Laboratories.....	121
6.3	AccuraGen Inc.	122
6.4	Adaptive Biotechnologies.....	123
6.5	Aethlon Medical	124
6.6	Agilent/Dako	125
6.7	Anchor Dx.....	127
6.8	ANGLE plc.....	128
6.9	ARUP Laboratories.....	129
6.10	AVIVA Systems Biology.....	131
6.11	Baylor Miraca Genetics Laboratories	132
6.12	Beckman Coulter Diagnostics.....	133
6.13	Becton, Dickinson and Company	134
6.14	BGI Genomics Co. Ltd	136
6.15	BillionToOne	138
6.16	Bioarray Genetics.....	139
6.17	Biocartis.....	140
6.18	Biocept, Inc.....	141
6.19	Biodesix Inc.	142
6.20	BioFluidica.....	143

6.21	BioGenex	144
6.22	BioIVT	145
6.23	Biolidics Ltd.....	146
6.24	bioMérieux Diagnostics.....	147
6.25	Bioneer Corporation	149
6.26	Bio-Rad Laboratories, Inc.....	150
6.27	Bio-Reference Laboratories.....	152
6.28	Bio-Techne	153
6.29	Bioview	154
6.30	Bolidics	155
6.31	Boreal Genomics.....	156
6.32	Bristol-Myers Squibb.....	157
6.33	Burning Rock.....	158
6.34	Cardiff Oncology	159
6.35	Caris Molecular Diagnostics	160
6.36	Castle Biosciences, Inc.	161
6.37	Celemics	162
6.38	CellCarta	163
6.39	CellMax Life	164
6.40	Cepheid (Danaher)	165
6.41	Charles River Laboratories.....	167
6.42	Circulogene.....	168
6.43	Cizzle Biotech	169
6.44	Clinical Genomics	170
6.45	Cytolumina Technologies Corp.	171
6.46	Datar Cancer Genetics Limited.....	172
6.47	Diagnologix LLC.....	173
6.48	Diasorin S.p.A.....	174

6.49	Dxcover.....	176
6.50	Enzo Biochem.....	177
6.51	Epic Sciences.....	178
6.52	Epigenomics AG.....	179
6.53	Eurofins Scientific.....	180
6.54	Exact Sciences.....	182
6.55	Fabric Genomics.....	183
6.56	Fluxion Biosciences.....	184
6.57	Freenome.....	185
6.58	FUJIFILM Wako Diagnostics.....	186
6.59	Fulgent Genetics.....	187
6.60	Fyr Diagnostics.....	188
6.61	GeneFirst Ltd.....	189
6.62	Genetron Holdings.....	190
6.63	GenomOncology.....	191
6.64	GILUPI Nanomedizin.....	192
6.65	Guardant Health.....	193
6.66	HansaBiomed.....	194
6.67	HeiScreen.....	195
6.68	Helomics.....	196
6.69	HTG Molecular Diagnostics.....	197
6.70	iCellate.....	198
6.71	ICON PLC.....	199
6.72	Illumina.....	200
6.73	Incell Dx.....	201
6.74	Inivata.....	202
6.75	INOVIQ.....	203
6.76	Integrated Diagnostics.....	204

6.77	Invitae Corporation.....	205
6.78	Invivogen	206
6.79	Invivoscribe	207
6.80	Janssen Diagnostics	208
6.81	Lunglife AI Inc	209
6.82	MDNA Life SCIENCES, Inc.....	210
6.83	MDx Health	211
6.84	Menarini Silicon Biosystems.....	212
6.85	Mesa Laboratories, Inc.	213
6.86	Millipore Sigma	214
6.87	Miltenyi Biotec	215
6.88	miR Scientific.....	216
6.89	Myriad Genetics/Myriad RBM	217
6.90	NantHealth, Inc.	218
6.91	Natera	219
6.92	NeoGenomics	220
6.93	NGeneBio.....	221
6.94	Novogene Bioinformatics Technology Co., Ltd.....	223
6.95	Oncocyte.....	225
6.96	OncoDNA	226
6.97	Ortho Clinical Diagnostics	227
6.98	Oxford Nanopore Technologies	228
6.99	PamGene	229
6.100	Panagene.....	230
6.101	Perkin Elmer.....	231
6.102	Personal Genome Diagnostics.....	232
6.103	Personalis.....	233
6.104	Precipio	234

6.105	Precision Medicine Group	235
6.106	PrecisionMed	236
6.107	Predicine	237
6.108	Promega	238
6.109	Qiagen	240
6.110	Rarecells SAS.....	242
6.111	RareCyte.....	243
6.112	Roche Molecular Diagnostics	244
6.113	ScreenCell	246
6.114	Sema4 Holdings.....	247
6.115	Sense Biodetection	248
6.116	Siemens Healthineers	249
6.117	simfo GmbH	250
6.118	Singlera Genomics Inc.....	251
6.119	Singulomics	252
6.120	SkylineDx	253
6.121	Standard BioTools	254
6.122	Sysmex Inostics.....	255
6.123	Tempus Labs, Inc.	256
6.124	Thermo Fisher Scientific Inc.....	257
6.125	Todos Medical	259
6.126	Variantyx	260
6.127	Veracyte	261
6.128	Volition	262
6.129	Vortex Biosciences	263
6.130	Vyant Bio.....	264
6.131	Zhejiang Orient Gene Biotech	265
7	The Global Market for MDx Cancer	266

7.1	MDx Cancer – Global Market Overview by Country	267
7.1.1	Table – Global Market by Country.....	267
7.1.2	Chart - Global Market by Country	268
7.2	Global Market by Cancer Type - Overview.....	269
7.2.1	Table – Global Market by Cancer Type	269
7.2.2	Chart – Global Market by Cancer Type – Base/Final Comparison	270
7.2.3	Chart – Global Market by Cancer Type – Base Year	271
7.2.4	Chart – Global Market by Cancer Type –Final Year.....	272
7.2.5	Chart – Global Market by Cancer Type – Share by Year	273
7.2.6	Chart – Global Market by Cancer Type – Segment Growth	274
7.3	Global Market by Product Type - Overview	275
7.3.1	Table – Global Market by Product Type.....	275
7.3.2	Chart – Global Market by Product Type – Base/Final Comparison	276
7.3.3	Chart – Global Market by Product Type – Base Year.....	277
7.3.4	Chart – Global Market by Product Type –Final Year	278
7.3.5	Chart – Global Market by Product Type – Share by Year.....	279
7.3.6	Chart – Global Market by Product Type – Segment Growth.....	280
7.4	Global Market by Place - Overview	281
7.4.1	Table – Global Market by Place.....	281
7.4.2	Chart – Global Market by Place – Base/Final Comparison	282
7.4.3	Chart – Global Market by Place – Base Year.....	283
7.4.4	Chart – Global Market by Place –Final Year.....	284
7.4.5	Chart – Global Market by Place – Share by Year.....	285
7.4.6	Chart – Global Market by Place – Segment Growth	286
8	Global Market by Cancer Type	287
8.1	MDx Breast Cancer.....	288
8.1.1	Table Breast Cancer Testing – by Country	288
8.1.2	Chart - Breast Cancer Testing Growth.....	289

8.2	MDx Colorectal Cancer	290
8.2.1	Table Colorectal Cancer Testing – by Country.....	290
8.2.2	Chart - Colorectal Cancer Testing Growth.....	291
8.3	MDx Cervical Cancer	292
8.3.1	Table Cervical Cancer Testing – by Country	292
8.3.2	Chart - Cervical Cancer Testing Growth.....	293
8.4	MDx Lung Cancer	294
8.4.1	Table Lung Cancer Testing – by Country	294
8.4.2	Chart - Lung Cancer Testing Growth.....	295
8.5	MDx Prostate	296
8.5.1	Table Prostate Testing – by Country.....	296
8.5.2	Chart - Prostate Testing Growth	297
8.6	MDx Melanoma Cancer	298
8.6.1	Table Melanoma Cancer Testing – by Country.....	298
8.6.2	Chart - Melanoma Cancer Testing Growth	299
8.7	MDx Blood.....	300
8.7.1	Table Blood Testing – by Country	300
8.7.2	Chart - Blood Testing Growth	301
8.8	MDx Companion Dx Development.....	302
8.8.1	Table Companion Dx Development – by Country.....	302
8.8.2	Chart - Companion Dx Development Growth	303
8.9	MDx Other Cancer	304
8.9.1	Table Other Cancer Testing – by Country.....	304
8.9.2	Chart - Other Cancer Testing Growth	305
9	Global Market by Product Type.....	306
9.1	MDx Instruments	307
9.1.1	Table Instruments – by Country	307
9.1.2	Chart - Instruments Growth.....	308

9.2	MDx Reagents	309
9.2.1	Table Reagents – by Country	309
9.2.2	Chart - Reagents Growth	310
9.3	MDx Software and Services.....	311
9.3.1	Table Software and Services – by Country.....	311
9.3.2	Chart - Software and Services Growth.....	312
10	Global Market by Place	313
10.1	MDx Clinical Laboratory	314
10.1.1	Table Clinical Laboratory – by Country	314
10.1.2	Chart - Clinical Laboratory Growth	315
10.2	MDx Pharmaceutical	316
10.2.1	Table Pharmaceutical – by Country	316
10.2.2	Chart - Pharmaceutical Growth	317
10.3	MDx Research	317
10.3.1	Table Research – by Country	318
10.3.2	Chart - Research Growth.....	319
11	Cancer Treatment and Trials.....	320
11.1	FDA Approvals by Year and Application.....	321
11.2	Clinical Trials Starts.....	322
11.3	Prevalence of Cancer Treatments	323
12	Appendices.....	324
12.1	United States Medicare System: Clinical Laboratory Fees Schedule	324
12.2	The Most Used IVD Assays.....	402
12.3	The Highest Grossing Assays	407
12.4	FDA Approved Human Genetic Tests.....	411
12.5	FDA Approved Pharmacogenomics Tests	416

Table of Tables

Table 1 Clinical Laboratory Departments and Segments	37
Table 2 Laboratory Management Focus – Different Approaches	38
Table 3 Key Segmentation Variables Going Forward.....	39
Table 4 Five Factors Driving Growth	44
Table 5 Factors Limiting Growth	48
Table 6 Seven Key Diagnostic Laboratory Technology Trends	50
Table 7 Global MDx Cancer Market by Region.....	267
Table 8 Global Market by Cancer Type	269
Table 9 Global Market by Product Type.....	275
Table 10 Global Market by Place.....	281
Table 11 MDx Breast Cancer by Country	288
Table 12 MDx Colorectal Cancer by Country.....	290
Table 13 Cervical Cancer Testing by Country	292
Table 14 Lung Cancer Testing by Country	294
Table 15 Prostate Testing by Country.....	296
Table 16 Melanoma Cancer Testing by Country	298
Table 17 MDx Blood by Country	300
Table 18 MDx Companion Dx Development by Country	302
Table 19 MDx Other Cancer Testing by Country	304
Table 20 MDx Instruments by Country.....	307
Table 21 MDx Reagents by Country.....	309
Table 22 Software and Services by Country.....	311
Table 23 MDx Clinical Laboratory by Country.....	314
Table 24 MDx Pharmaceutical by Country	316
Table 25 Research by Country	318

Table 26 Clinical Lab Fee Schedule	324
Table 1 The Most Common Assays.....	402
Table 2 Largest Revenue Assays.....	407

Table of Figures

Figure 1 Global Healthcare Spending	33
Figure 2 The Lab Test Pie	35
Figure 3 Population by Age Group	46
Figure 4 Health Care Consumption by Age	46
Figure 5 Cancer Incidence - Age at Diagnosis.....	47
Figure 6 Centralized vs. Decentralized Laboratory Service	51
Figure 7 A Highly Multiplexed Syndromic Testing Unit.....	51
Figure 8 The Real Cost to Sequence the Human Genome.....	53
Figure 9 The Codevelopment Process	55
Figure 10 Comparing MDx Diagnostic and Traditional Testing.....	56
Figure 11 Global Market Shares Base Year.....	268
Figure 12 MDx Market by Cancer - Base vs. Final	270
Figure 13 Cancer Market Base Year	271
Figure 14 Cancer Market Final Year.....	272
Figure 15 MDx Cancer Share by Year	273
Figure 16 MDx Cancer Segment Growth Rates	274
Figure 17 MDx Market by Product - Base vs. Final.....	276
Figure 18 Product Market Base Year	277
Figure 19 Product Market Final Year	278
Figure 20 MDx Product Share by Year	279
Figure 21 MDx Product Segment Growth Rates.....	280
Figure 22 MDx Market by Place - Base vs. Final.....	282
Figure 23 Place Market Base Year.....	283
Figure 24 Place Market Final Year	284
Figure 25 MDx Place Share by Year	285

Figure 26 MDx Place Segment Growth Rates	286
Figure 27 Breast Cancer Testing Growth.....	289
Figure 28 Colorectal Cancer Testing Growth.....	291
Figure 29 Cervical Cancer Testing Growth.....	293
Figure 30 Lung Cancer Testing Growth.....	295
Figure 31 Prostate Testing Growth.....	297
Figure 32 Melanoma Cancer Testing Growth	299
Figure 33 Blood Testing Growth	301
Figure 34 Companion Dx Development Growth	303
Figure 35 Other Cancer Testing Growth	305
Figure 36 Instruments Growth	308
Figure 37 Reagents Growth	310
Figure 38 Software and Services Growth.....	312
Figure 39 Clinical Laboratory Growth	315
Figure 40 Pharmaceutical Growth	317
Figure 41 Research Growth.....	319
Figure 42 FDA Approvals by Year and Application	321
Figure 43 Clinical Trials for Oncology by Year	322
Figure 44 Pie Chart of Prevalence of Cancer Treatments	323